356 related articles for article (PubMed ID: 35753176)
1. Ocrelizumab during pregnancy and lactation: Rationale and design of the MINORE and SOPRANINO studies in women with MS and their infants.
Bove R; Hellwig K; Pasquarelli N; Borriello F; Dobson R; Oreja-Guevara C; Lin CJ; Zecevic D; Craveiro L; McElrath T; Vukusic S
Mult Scler Relat Disord; 2022 Aug; 64():103963. PubMed ID: 35753176
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder.
Ciplea AI; Langer-Gould A; de Vries A; Schaap T; Thiel S; Ringelstein M; Gold R; Hellwig K
Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32327455
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD20 monoclonal antibody therapy in postpartum women with neurological conditions.
Anderson A; Rowles W; Poole S; Balan A; Bevan C; Brandstadter R; Ciplea AI; Cooper J; Fabian M; Hale TW; Jacobs D; Kakara M; Krysko KM; Longbrake EE; Marcus J; Repovic P; Riley CS; Romeo AR; Rutatangwa A; West T; Hellwig K; LaHue SC; Bove R
Ann Clin Transl Neurol; 2023 Nov; 10(11):2053-2064. PubMed ID: 37675826
[TBL] [Abstract][Full Text] [Related]
4. Pregnancy outcomes of women with multiple sclerosis treated with ocrelizumab in Canada: A descriptive analysis of real-world data.
Gitman V; Stavropoulos A; Saenz V; Pasquarelli N; Zecevic D; Devonshire V
Mult Scler Relat Disord; 2022 Jun; 62():103792. PubMed ID: 35452964
[TBL] [Abstract][Full Text] [Related]
5. Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation.
Proschmann U; Haase R; Inojosa H; Akgün K; Ziemssen T
Front Immunol; 2021; 12():715195. PubMed ID: 34512637
[TBL] [Abstract][Full Text] [Related]
6. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development.
Matro R; Martin CF; Wolf D; Shah SA; Mahadevan U
Gastroenterology; 2018 Sep; 155(3):696-704. PubMed ID: 29857090
[TBL] [Abstract][Full Text] [Related]
7. Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts - the CONFIDENCE study protocol.
Dirks P; Zingler V; Leemhuis J; Berthold H; Hieke-Schulz S; Wormser D; Ziemssen T
BMC Neurol; 2020 Mar; 20(1):95. PubMed ID: 32171264
[TBL] [Abstract][Full Text] [Related]
8. Ocrelizumab exposure in the second trimester of pregnancy without neonatal B-cell depletion.
Rolfes M; Rutatangwa A; Waubant E; Krysko KM
Mult Scler Relat Disord; 2020 Oct; 45():102398. PubMed ID: 32707531
[TBL] [Abstract][Full Text] [Related]
9. Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.
Hauser SL; Bar-Or A; Weber MS; Kletzl H; Günther A; Manfrini M; Model F; Mercier F; Petry C; Wing Q; Koendgen H; Smith T; Kappos L
Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36792367
[TBL] [Abstract][Full Text] [Related]
10. Effect on breastfeeding practices of providing in-home lactation support to vulnerable women through the Canada Prenatal Nutrition Program: protocol for a pre/post intervention study.
Mildon A; Francis J; Stewart S; Underhill B; Ng YM; Richards E; Rousseau C; Di Ruggiero E; Dennis CL; O'Connor DL; Sellen DW
Int Breastfeed J; 2021 Jul; 16(1):49. PubMed ID: 34215288
[TBL] [Abstract][Full Text] [Related]
11. Neonatal B-Cell Levels and Infant Health in Newborns Potentially Exposed to Anti-CD20 Monoclonal Antibodies During Pregnancy or Lactation.
Schwake C; Steinle J; Thiel S; Timmesfeld N; Haben S; Ayzenberg I; Gold R; Hellwig K
Neurol Neuroimmunol Neuroinflamm; 2024 Jul; 11(4):e200264. PubMed ID: 38870458
[TBL] [Abstract][Full Text] [Related]
12. Outcome of infants exposed to olanzapine during breastfeeding.
Gilad O; Merlob P; Stahl B; Klinger G
Breastfeed Med; 2011 Apr; 6(2):55-8. PubMed ID: 21034242
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer, pregnancy, and breastfeeding.
Helewa M; Lévesque P; Provencher D; Lea RH; Rosolowich V; Shapiro HM;
J Obstet Gynaecol Can; 2002 Feb; 24(2):164-80; quiz 181-4. PubMed ID: 12196882
[TBL] [Abstract][Full Text] [Related]
15. Levetiracetam in lactation: How much is excreted into human breast milk?
Dinavitser N; Kohn E; Berlin M; Brandriss N; Bar-Chaim A; Keidar R; Livne A; Stepensky D; Berkovitch M; Sheinberg R
Br J Clin Pharmacol; 2022 Jan; 88(1):199-205. PubMed ID: 34131926
[TBL] [Abstract][Full Text] [Related]
16. Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy.
Moccia M; Affinito G; Berera G; Marrazzo G; Piscitelli R; Carotenuto A; Petracca M; Lanzillo R; Triassi M; Brescia Morra V; Palladino R
J Neurol; 2022 Dec; 269(12):6504-6511. PubMed ID: 35953597
[TBL] [Abstract][Full Text] [Related]
17. Comparing infusion-related reactions of the first full dose (600 mg) biosimilar ocrelizumab administration with the standard divided protocol in multiple sclerosis patients: a randomized controlled trial study.
Abbasi Kasbi N; Ghadiri F; Sahraian MA; Nahayati MA; Moghadasi AN; Langroodi HG; Poursadeghfard M; Hosseini S; Heidari H; Baghbanian SM; Kamali H; Ameli Z; Shahmohammadi S; Navardi S
Acta Neurol Belg; 2024 Feb; 124(1):205-212. PubMed ID: 37715074
[TBL] [Abstract][Full Text] [Related]
18. Impact of interferon beta exposure on birth outcome and child development - Results from the post-authorisation safety study PRIMA.
Klehmet J; Begus-Nahrmann Y; Taipale K; Niemczyk G; Rehberg-Weber K
Mult Scler Relat Disord; 2023 Sep; 77():104844. PubMed ID: 37393802
[TBL] [Abstract][Full Text] [Related]
19. Contraceptive effects of extended lactational amenorrhoea: beyond the Bellagio Consensus.
Short RV; Lewis PR; Renfree MB; Shaw G
Lancet; 1991 Mar; 337(8743):715-7. PubMed ID: 1672186
[TBL] [Abstract][Full Text] [Related]
20. Maternal, fetal, neonatal and breastmilk flecainide concentration during maternal therapy and lactation: a case report.
van der Zande JA; Cornette JMJ; Roos-Hesselink JW; Flint RB
Int Breastfeed J; 2023 Apr; 18(1):21. PubMed ID: 37060099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
